OBJECTIVE: To quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA). METHODS: Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Disease activity in SLE patients was assessed by the SLE Disease Activity Index. RESULTS: Increased serum sFas/APO-1 levels were observed in only 1 of the 27 SLE patients (4%) and 3 of the 10 JRA patients (30%). CONCLUSION: Increased levels of sFas/APO-1 occurred infrequently in SLE, and the levels were lower than 10 ng/ml. Increased levels of sFas/APO-1 are not specific for SLE. Soluble Fas/APO-1 is unlikely to be of major pathogenetic significance in SLE.
OBJECTIVE: To quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA). METHODS: Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Disease activity in SLEpatients was assessed by the SLE Disease Activity Index. RESULTS: Increased serum sFas/APO-1 levels were observed in only 1 of the 27 SLEpatients (4%) and 3 of the 10 JRA patients (30%). CONCLUSION: Increased levels of sFas/APO-1 occurred infrequently in SLE, and the levels were lower than 10 ng/ml. Increased levels of sFas/APO-1 are not specific for SLE. Soluble Fas/APO-1 is unlikely to be of major pathogenetic significance in SLE.
Authors: T Otsuki; H Sakaguchi; A Tomokuni; T Aikoh; T Matsuki; Y Kawakami; M Kusaka; H Ueki; S Kita; A Ueki Journal: Immunology Date: 1998-06 Impact factor: 7.397
Authors: Y Tokano; S Miyake; N Kayagaki; K Nozawa; S Morimoto; M Azuma; H Yagita; Y Takasaki; K Okumura; H Hashimoto Journal: J Clin Immunol Date: 1996-09 Impact factor: 8.317
Authors: A Tomokuni; T Aikoh; T Matsuki; Y Isozaki; T Otsuki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki Journal: Clin Exp Immunol Date: 1997-11 Impact factor: 4.330